Suppr超能文献

Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.

作者信息

Fitchett David

机构信息

St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Can J Diabetes. 2015 Dec;39 Suppl 5:S176-82. doi: 10.1016/j.jcjd.2015.09.083.

Abstract
摘要

相似文献

1
Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
Can J Diabetes. 2015 Dec;39 Suppl 5:S176-82. doi: 10.1016/j.jcjd.2015.09.083.
2
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
J Diabetes Complications. 2017 Dec;31(12):1719-1727. doi: 10.1016/j.jdiacomp.2017.08.005. Epub 2017 Aug 12.
3
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
J Diabetes Complications. 2013 May-Jun;27(3):280-6. doi: 10.1016/j.jdiacomp.2012.12.004. Epub 2013 Feb 1.
4
The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Can J Diabetes. 2015 Dec;39 Suppl 5:S155-9. doi: 10.1016/j.jcjd.2015.09.009.
5
Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
Nutr Metab Cardiovasc Dis. 2013 Jul;23(7):591-8. doi: 10.1016/j.numecd.2013.03.007. Epub 2013 May 24.
6
New Insulins, Biosimilars, and Insulin Therapy.
Diabetes Technol Ther. 2017 Feb;19(S1):S42-S58. doi: 10.1089/dia.2017.2505.
7
New Medications for the Treatment of Diabetes.
Diabetes Technol Ther. 2017 Feb;19(S1):S128-S140. doi: 10.1089/dia.2017.2512.
9
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54. doi: 10.1016/j.jcjd.2015.09.090.
10
Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
Diabetes Obes Metab. 2015 Apr;17(4):335-42. doi: 10.1111/dom.12380. Epub 2014 Sep 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验